Capítulo 30 · Pharmaceutical products
3003.39.00
Other
- 3003 Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale
- - Other, containing hormones or other products of heading 29.37:
- - - Other
Thuốc (trừ các mặt hàng thuộc nhóm 30.02, 30.05 hoặc 30.06) gồm từ hai hoặc nhiều thành phần trở lên đã pha trộn với nhau dùng cho phòng bệnh hoặc chữa bệnh, chưa được đóng gói theo liều lượng hoặc làm thành hình dạng nhất định hoặc đóng gói để bán lẻ / - Loại khác, chứa hormon hoặc các sản phẩm khác thuộc nhóm 29.37: / - - Loại khác
Impostos aplicáveis em 2026
Fonte: pauta consolidada BT2026 (atualizada em 05/04/2026)Taxas preferenciais especiais (ACL) – 2026
| FTA | Taxa | Base dos dados | Prova de origem | Base jurídica | Estado |
|---|---|---|---|---|---|
| AANZFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2022 - 2027 (một mức cho cả giai đoạn) |
AANZ | 121/2022/NĐ-CP | Ad valorem |
| ACFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2022 - 2027 (một mức cho cả giai đoạn) |
E | 118/2022/NĐ-CP | Ad valorem |
| AHKFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
AHK | 123/2022/NĐ-CP | Ad valorem |
| AIFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 01/01/2026 - 31/12/2026 |
AI | 122/2022/NĐ-CP | Ad valorem |
| AJCEP | 0% Mais baixa publicada | Pauta consolidada BT2026 01/4/2026 - 31/3/2027 |
AJ | 120/2022/NĐ-CP | Ad valorem |
| AKFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2022 - 2027 (một mức cho cả giai đoạn) |
AK | 119/2022/NĐ-CP | Ad valorem |
| ATIGA | 0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
D | 126/2022/NĐ-CP | Ad valorem |
| CPTPP | 0% Mais baixa publicada | Pauta consolidada BT2026 (VI) |
CPTPP | 115/2022/NĐ-CP | Ad valorem |
| EVFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
EUR.1 | 116/2022/NĐ-CP | Ad valorem |
| RCEP (Anexo A) BN, KH, ID, LA, MY, MM, PH, SG, TH |
0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Anexo B) AU |
0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Anexo C) CN |
0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Anexo D) JP |
0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Anexo E) KR |
0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Anexo F) NZ |
0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| UKVFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
EUR.1 | 117/2022/NĐ-CP | Ad valorem |
| VCFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
VC | 112/2022/NĐ-CP | Ad valorem |
| VJEPA | 0% Mais baixa publicada | Pauta consolidada BT2026 01/4/2026 - 31/3/2027 |
JV · Form VJ | 124/2022/NĐ-CP | Ad valorem |
| VKFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
VK | 125/2022/NĐ-CP | Ad valorem |
| VN-LAO | 0% Mais baixa publicada | Pauta consolidada BT2026 | S | 206/2025/NĐ-CP | Ad valorem |
| VIFTA | 0% Mais baixa publicada | Pauta consolidada BT2026 2026 |
Form VI (verify) | 131/2024/NĐ-CP | Ad valorem |
| VN-CAM | Sem dados | Sem dados | S | 56/2026/NĐ-CP | Sem dados |
| VNCU | Sem dados | Sem dados | VNCB · Form VC (Cuba) | 114/2022/NĐ-CP | Sem dados |
| VN-EAEU | * não elegível | Pauta consolidada BT2026 2026 |
EAV | 113/2022/NĐ-CP | Não elegível (*) |
Uma taxa publicada não significa que as mercadorias sejam elegíveis. É necessário cumprir as regras de origem e dispor de uma prova de origem válida.
Executar o Smart Tariff Advisory Comparar ACL Calcular impostos
Histórico de taxas / desagravamento por ano
Das folhas das listas de ACL 2022–2027
| FTA | Períodos |
|---|---|
| ACFTA AC · linha 4481 |
2022 - 2027 (một mức cho cả giai đoạn)0%
|
| ATIGA AT · linha 4442 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| AJCEP AJ · linha 4480 |
30/12/2022 - 31/3/20230%
01/4/2023 - 31/3/20240%
01/4/2024 - 31/3/20250%
01/4/2025 - 31/3/20260%
01/4/2026 - 31/3/20270%
01/4/2027 - 31/3/20280%
|
| VJEPA VJ · linha 4484 |
30/12/2022 - 31/3/20230%
01/4/2023 - 31/3/20240%
01/4/2024 - 31/3/20250%
01/4/2025 - 31/3/20260%
01/4/2026 - 31/3/20270%
01/4/2027 - 31/3/20280%
|
| AKFTA AK · linha 4484 |
2022 - 2027 (một mức cho cả giai đoạn)0%
Taxa com exclusões: 0 |
| AANZFTA AANZ · linha 4448 |
2022 - 2027 (một mức cho cả giai đoạn)0%
Coluna de taxa F (oculta): 0 |
| AIFTA AI · linha 4444 |
30/12/20220%
31/12/2022 - 30/12/20230%
31/12/2023 - 30/12/20240%
31/12/2024 - 31/12/20250%
01/01/2026 - 31/12/20260%
01/01/2027 - 31/12/20270%
|
| VKFTA VK · linha 4444 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VCFTA VC · linha 4491 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VN-EAEU EAV · linha 4488 |
2022* não elegível
2023* não elegível
2024* não elegível
2025* não elegível
2026* não elegível
2027* não elegível
|
| AHKFTA AKH · linha 4496 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| EVFTA EV-NK · linha 4467 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| UKVFTA UKV · linha 4469 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| CPTPP CPTPP · linha 4467 |
(I) → 2021*0%
(II) → 2022*0%
(III) → 2023*0%
(IV) → 2024*0%
(V) → 2025*0%
(VI) → 2026*0%
(VII) → 2027*0%
|
| RCEP A RCEPT-A · linha 4488 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP B B · linha 4488 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP C C · linha 4488 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP D D · linha 4488 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP E E · linha 4491 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP F F · linha 4488 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VIFTA VI · linha 4131 |
20240%
20250%
20260%
20270%
Coluna auxiliar J: 8 |
* Os períodos do CPTPP (I)–(VII) são associados a anos por comparação com a BT2026 (dados DERIVADOS – verificar).
Aconselhamento e avisos
Avaliação geral (a origem não é considerada). Execute o Smart Tariff Advisory para uma avaliação específica da origem.
YELLOW – REVIEW REQUIRED TAX-001 Several VAT rates
- Descrição
- The VAT column shows "5/8/10".
- Referência jurídica
- 181/2025/NĐ-CP
- Ação recomendada
- Determine the VAT rate by the nature of goods and reduction rules (174/2025/NĐ-CP, Annex I/II).
- Estado da verificação
- Não verificado – verificação necessária
GRAY – DATA UNAVAILABLE TR-004 Not Assessed – Additional Regulatory Verification Required
- Descrição
- The source file records no trade remedy for 3003.39.00. This does NOT mean there is no risk.
- Ação recomendada
- Check the MOIT Trade Remedies Authority database.
- Estado da verificação
- Não verificado – verificação necessária
GREEN – VERIFIED DQ-001 MFN rate present in the source
- Descrição
- The MFN rate 0% for 3003.39.00 was checked against BT2026 (cell BT2026!N4560), basis 26/2023/NĐ-CP.
- Referência jurídica
- 26/2023/NĐ-CP
- Ação recomendada
- Verification scope: matched against source file version 2026.04.05; not a substitute for the legal text.
- Estado da verificação
- Confrontado com o ficheiro pautal de origem
Notas de capítulo
Notes
1. This Chapter does not cover:
(a) Foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV);
(b) Products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 24.04);
(c) Plasters specially calcined or finely ground for use in dentistry (heading 25.20);
(d) Aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 33.01);
(e) Preparations of headings 33.03 to 33.07, even if they have therapeutic or prophylactic properties;
(f) Soap or other products of heading 34.01 containing added medicaments;
(g) Preparations with a basis of plaster for use in dentistry (heading 34.07);
(h) Blood albumin not prepared for therapeutic or prophylactic uses (heading 35.02); or
(ij) Diagnostic reagents of heading 38.22.
2. For the purposes of heading 30.02, the expression “immunological products” applies to peptides and proteins (other than goods of heading 29.37) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumor necrosis factors (TNF), growth factors (GF), hematopoietins and colony stimulating factors (CSF).
3. For the purposes of headings 30.03 and 30.04 and of Note 4 (d) to this Chapter, the following are to be treated:
(a) As unmixed products:
(1) Unmixed products dissolved in water;
(2) All goods of Chapter 28 or 29; and
(3) Simple vegetable extracts of heading 13.02, merely standardised or dissolved in any solvent;
(b) As products which have been mixed:
(1) Colloidal solutions and suspensions (other than colloidal sulphur);
(2) Vegetable extracts obtained by the treatment of mixtures of vegetable materials; and
(3) Salts and concentrates obtained by evaporating natural mineral waters.
4. Heading 30.06 applies only to the following, which are to be classified in that heading and in no other heading of the Nomenclature:
(a) Sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure;
(b) Sterile laminaria and sterile laminaria tents;
(c) Sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable;
(d) Opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses;
(e) Placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments;
(f) Dental cements and other dental fillings; bone reconstruction cements;
(g) First-aid boxes and kits;
(h) Chemical contraceptive preparations based on hormones, on other products of heading 29.37 or on spermicides;
(ij) Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments;
(k) Waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and
(l) Appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates.
Subheading Notes
1. For the purposes of subheadings 3002.13 and 3002.14, the following are to be treated:
(a) As unmixed products, pure products, whether or not containing impurities;
(b) As products which have been mixed:
(1) The products mentioned in (a) above dissolved in water or in other solvents;
(2) The products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and
(3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive.
2. Subheadings 3003.60 and 3004.60 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients: amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN).
(*): Dạng uống là dạng sử dụng qua đường miệng (ví dụ, nuốt, nhai, ngậm, đặt dưới lưỡi…)
(SEN): Tham khảo Chú giải bổ sung (SEN) của Danh mục Thuế quan hài hòa ASEAN (AHTN) 2022